Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 BI5 and BI7 genes

Prostate

Volumn 68, Issue 8, 2008, Pages 839-848

  Bao, Bo Ying ^a   Chuang, Bin Fay ^a   Wang, Qianben ^a   Sartor, Oliver ^a   Balk, Steven P ^b   Brown, Myles ^a   Kantoff, Philip W ^a   Lee, Gwo Shu Mary ^a,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c D710B ^*  (United States)

Author keywords

Androgen; Androgen receptor; Prostate cancer; UGT2B15; UGT2B17

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; FLUTAMIDE; GLUCURONOSYLTRANSFERASE; RNA; UDP GLUCURONOSYLTRANSFERASE 2B15; UDP GLUCURONOSYLTRANSFERASE 2B17;

ARTICLE; CANCER CELL CULTURE; CELL STRAIN LNCAP; CHROMATIN IMMUNOPRECIPITATION; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; EXPERIMENT; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TREATMENT RESPONSE; UPREGULATION;

CELL LINE, TUMOR; DIHYDROTESTOSTERONE; DOWN-REGULATION; GENE EXPRESSION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA INTERFERENCE;

EID: 45349098272     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20749     Document Type: Article

References (34)

1. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25(2):276-308.
2. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002;20:3001-3015.
3. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1(1):34-45.
4. Balk SP. Androgen receptor as a target in androgen independent prostate cancer. Urology 2002;60:132-138.
5. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, Reuter V, Gerald WL. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217-227.
6. Mohler JL, Gregory CW, Ford OH III, Kim D, Weaver CM, Petrusz P, Wilson EM, French FS. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440-448.
7. Gregory CW, Hamil KG, Kim D, Hall SH, Pretlow TG, Mohler JL, French FS. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res 1998;58:5718-5724.
8. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-39.
9. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002;62:1008-1013.
10. Chang GT, Blok LJ, Steenbeek M, Veldscholte J, van Weerden WM, van Steenbrugge GJ, Brinkmann AO. Differentially expressed genes in androgen-dependent and -independent prostate carcinomas. Cancer Res 1997;57(18):4075-4081.
11. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66(5):2815-2825.
12. Beaulie M, Levesque E, Hum DW, Belanger A. Isolation and characterization of a novel cDNA encoding a human UDP-glucuronosyltransferase active on C19 steroids. J Biol Chem 1996;271:22855-22862.
13. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: Metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000;40:581-616.
14. Chouinard S, Pelletier G, Belanger A, Barbier O. Cellular specific expression of the androgen-conjugating enzymes UGT2B15 and UGT2B17 in the human prostate epithelium. Endocr Res 2004;30(4):717-725.
15. Belanger A, Brochu M, Lacoste D, Noël C, Labrie F, Dupont A, Cusan L, Caron S, Couture J. Steroid glucuronides: Human circulatory levels and formation by LNCaP cells. J Steroid Biochem Mol Biol 1991;40(4-6):593-598.
16. Roy AK. Regulation of steroid hormone action in target cells by specific hormone-inactivating enzymes. Proc Soc Exp Biol Med 1992;199(3):265-272.
17. Chouinard S, Barbier O, Belanger A. UDP-glucuronosyltransferase (UGT)2B15 and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells. J Bio Chem 2007;282(46):33466-33474.
18. Kanaya J, Takashima M, Koh E, Namiki M. Androgen-independent growth in LNCaP cell lines and steroid uridine diphosphate-glucuronosyltransferase expression. Asian J Androl 2003;5(1):9-13.
19. Guillemette C, Hum DW, Belanger A. Regulation of steroid glucuronosyltransferase activities and transcripts by androgen in the human prostatic cancer LNCaP cell line. Endocrinology 1996;137(7):2872-2879.
20. Guillemette C, Levesque E, Beaulieu M, Turgeon D, Hum DW, Belanger A. Differential regulation of two uridine diphosphoglucuronosyltransferases, UGT2B15 and UGT2B17, in human prostate LNCaP cells. Endocrinology 1997;138(7):2998-3005.
21. Harrington WR, Sengupta S, Katzenellenbogen BS. Estrogen regulation of the glucuronidation enzyme UGT2B15 in estrogen receptor-positive breast cancer cells. Endocrinology 2006;147(8):3843-3850.
22. Coleman IM, Kiefer JA, Brown LG, Pitts TE, Nelson PS, Brubaker KD, Vessella RL, Corey E. Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes. Neoplasis 2006;8(10):862-878.
23. Bao BY, Yeh SD, Lee YF. 1alpha, 25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases. Carcinogenesis 2006;27(1):32-42.
24. Wang Q, Carroll JS, Brown M. Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell 2005;19(5):631-642.
25. Wang Q, Li W, Liu XS, Carroll JS, Jänne OA, Keeton EK, Chinnaiyan AM, Pienta KJ, Brown M. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 2007;27:380-392.
26. Turgeon D, Carrier JS, Lévesque E, Beatty BG, Bélanger A, Hum DW. Isolation and characterization of the human UGT2B15 gene, localized within a cluster of UGT2B genes and pseudogenes on chromosome 4. J Mol Biol 2000;295:489-504.
27. Beaulieu M, Levesque E, Tchernof A, Beatty BG, Belanger A, Hum DW. Chromosomal localization, structure, and regulation of the UGT2B17 gene, encoding a C19 steroid metabolizing enzyme. DNA Cell Biol 1997;16(10):1143-1154.
28. Chouinard S, Pelletier G, Belanger A, Barbier O. Isoform-specific regulation of uridine diphosphate-glucuronosyltransferase 2B enzymes in the human prostate: Differential consequences for androgen and bioactive lipid inactivation. Endocrinology 2006;147:5431-5442.
29. Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S, Barnes AS, Tempany C, Catalona W, Kantoff PW, Oh WK. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005;11(14)5233-5240.
30. Fromont G, Chene L, Vidaud M, Vallancien G, Mangin P, Fournier G, Validire P, Latil A, Cussenot O. Differential expression of 37 selected genes in hormone-refractory prostate cancer using quantitative taqman real-time RT-PCR. Int J Cancer 2005;114(2):174-181.
31. Geller J, Albert JD, Nachtsheim DA, Loza D. Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy. J Urol 1984;132:693-696.
32. Nishiyama T, Hashimoto Y, Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 2004;10:7121-7126.
33. Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, Barone MV, Ametrano D, Zannini MS, Abbondanza C, Auricchio F. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J 2000;19:5406-5417.
34. Lee SR, Ramos SM, Ko A, Masiello D, Swanson KD, Lu ML, Balk SP. AR and ER interaction with a p21-Activated Kinase (PAKT6). Mol Endocrinol 2002;16(1):85-99.